Saturday, June 24, 2017
   
Text Size

GLOBAL FUND to Fight AIDS, Tuberculosis and Malaria


Bookmark and Share

Drug Resistant Tuberculosis

Institute of Human Virology Nigeria (IHVN) was selected in 2011 as the Principal Recipient of the Global Fund to Fight AIDS, Tuberculosis and Malaria Round 9 Multi-drug Resistant Tuberculosis (MDR-TB) Grant. The goal of the grant is to strengthen MDR-TB prevention and control in Nigeria. IHVN is partnering with the National Tuberculosis and Leprosy Control Program (NTBLCP) of the Federal Ministry of Health (FMoH) and other stakeholders in the implementation of the scale up of the programmatic management of drug resistant TB (PMDT). On receiving the Grant, the NTBLCP (also a Sub-Recipient to the grant), set up a coordinating mechanism for the MDR-TB program and supported IHVN and other partners in setting up implementation structures for intervention activities. Phase 1 recorded a recent grant rating of A1, with 168 patients commenced on treatment across seven treatment centres that were activated.

In Phase 2, the activities supported by the grant include infrastructural upgrade, supply of equipment and maintenance of some treatment centres and reference laboratories; and supply of reagents, consumables and data collection tools. The Institute also carried out capacity building for treatment centres, laboratory and state TB staff on service provision and data collection; sputum transportation logistics nationwide to increase case detection; strengthened routine surveillance for MDR-TB at all levels; and established and supported State MDR-TB Teams for strengthening oversight and supervision of patient

In 2015, IHVN was again selected by the Country Coordinating Mechanism of Nigeria as a Principal Recipient to implement the Global Fund New Funding Model (NFM) MDR TB grant. The current grant aims to reduce the DR-TB burden by complementing and accelerating the ongoing activities implemented by the Nigerian government and partners, in the single stream funding, through the Global Fund New Funding Model Grant.

Major task includes scaling up the activities in the round 9 Grant to improve accessibility to DR-TB diagnosis, care and treatment services. New activities in the NFM DR-TB grant include; LGA team trainings, decentralization of out- patient services for the DR-TB patients, development of structured adherence program for DR-TB, development of Logistic Management Information Systems for lab, support for electronic data management through the e-TB manager and GX Alert, maintenance of GeneXpert machines, procurement and distribution of GeneXpert cartridges, procurement of basic emergency equipment for treatment centers to manage critically ill patients and improve treatment outcome, solar powered refrigerators for sample storage to reduce sample wastage.

With support from the Global Fund and other partners, there have been 149,569 presumptive cases for DR-TB that have been tested for DR-TB, over 2800 patients have begun second-line treatment for DR-TB (July 2011 – December 2016). Also 1,608 service providers have been trained in the following areas: clinical and programmatic management of DR-TB, laboratory techniques for TB culture, DST and Line Probe Assay, DR-TB recording and reporting tools and data management, pharmaceutical practices and Logistic Management Information System and Community support for DR-TB patients. The treatment centres providing DR-TB services are:

  • Abubakar Tafawa Balewa University Teaching Hospital, Bauchi State
  • Jos University Teaching Hospital, Plateau State
  • University College Hospital, Ibadan (UCH), Oyo State
  • Government Chest Hospital, Jericho, Ibadan, Oyo State
  • University of Uyo Teaching Hospital, Uyo, (UUTH), Akwa-Ibom State
  • University of Port Harcourt Teaching Hospital, Port Harcourt (UPTH). Rivers State
  • Dr. Lawrence Henshaw Memorial Hospital, Calabar, Cross River State
  • National Tuberculosis and Leprosy Training Center, Zaria (NTBLTC), Kaduna State
  • Infectious Diseases Hospital, Kano State
  • Sacred Hearts Hospital, Abeokuta., Ogun State
  • Federal Medical Center Owerri, Imo State
  • State Specialist Hospital, Sokoto, Sokoto State
  • State Hospital Jalingo, Taraba
  • St. Vincent Alaide Benue State
  • General Hospital Iwo, Osun State

The currently operational TB Reference Laboratories are:

National Institute for Medical Research (National) National Tuberculosis Leprosy Training Center (National) University College Hospital (South West) Aminu Kano Teaching Hospital (North West) Dr. Lawrence Henshaw Memorial Hospital Calabar (South South), Zankli Hospital (North Central), Jos University Teaching Hospital, and University of Port Harcourt Teaching Hospital

In addition, IHVN partners with the following International Federation of Anti-Leprosy Associations (ILEP); (German Leprosy Relief Association (GLRA), Netherlands Leprosy Relief (NLR), Damien Foundation Belgium (DFB), The Leprosy Mission of Nigeria (TLMN) and Health Alive Foundation for state and community level activities.

Malaria

The Institute of Human Virology Nigeria (IHVN) has been implementing the Global Fund Malaria program, as a Sub-Recipient to the National Malaria Elimination Program (NMEP) from 2009 till date.

Over the past 7 years, the Institute has supported the components of malaria control interventions through selected public health facilities in 13 States - Katsina, Ogun, Kwara, Gombe, Akwa-Ibom, Kano, Kaduna, Borno, Kebbi, Plateau, Kogi, Benue and Jigawa States. Cumulatively, 417 public health facilities across 291 LGAs were supported to deliver free prompt and effective malaria services in their various communities.

Priority interventions supported includes;

  • Capacity building of health care providers and other relevant staff of the State Ministry of Health and LGA Department of Health.
  • Provision of drugs and commodities through the National Malaria Program to selected public health facilities to support free and accessible malaria prevention, diagnosis and treatment program as follows:
    • Long Lasting Insecticide Treated Nets targeted at pregnant women and children under 5 years through routine (ANC and immunization clinics) and continuous distribution channels using schools
    • Malaria Rapid Diagnostic Test kits (mRDTs) and Artemisinin-based Combination drugs for free diagnosis and treatment of malaria according to recommended treatment guidelines
    • Sulphadoxine/Pyrimethamine for Intermittent Prevention of Malaria in Pregnancy (IPTp)
    • Technical support for health systems strengthening activities as well as Logistics management information systems ( LMIS) for malaria commodities
    • Support for routine monitoring and evaluation, including supportive supervision and On-the-Job trainings (OJT)

Till date, IHVN has distributed over five million Long Lasting Insecticide Treated Nets through campaigns and routine /continuous distribution channels. About 9.8 million persons have been treated with ACTs and over seven million parasitological diagnosis done before treatment. Over 730,000 pregnant women have benefited from routine Sulphadoxine/Pyrimethamine for Intermittent Prevention of Malaria in Pregnancy (IPTp)

HIV

IHVN is a sub-recipient to FHI 360 implementing the Global Fund HIV New Funding Model (NFM) grant and providing services in the areas of HIV Testing and Counseling (HTC), prevention of mother-to-child transmission (PMTCT), anti-retroviral treatment (ART) and TB/HIV services in 73 comprehensive and 367 primary health care centers in Adamawa, Bauchi, Benue, Borno, Kano, Nasarawa, Ogun, Plateau, Taraba and Yobe states and the Federal Capital Territory.

:: Privacy Policy

IHVN frowns at reproduction of the content of this website without prior permission.This act is illegal and punishable under the law.

:: Support and Funding

The Institute of Human Virology, Nigeria AITRP Training Programmes are supported and funded by the Fogarty International Center.
FacebookTwitterGoogleYoutube

IHVN Member's Logon